H. Lundbeck A/S (HLUN-A.CO)
ValueMarkers Composite Index
91% below intrinsic value ($61)
H. Lundbeck A/S (HLUN-A.CO) — VMCI valuation read
Composite valuation read on HLUN-A.CO: VMCI 66/100 against a Healthcare sector median of 50. The 16-point above-median print is the headline number for H. Lundbeck A/S, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for HLUN-A.CO: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on HLUN-A.CO: HLUN-A.CO trades at 15.0x earnings, 17% below the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of 2.7x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
HLUN-A.CO rose 2.6% over the trailing 7 days, with a +1.8% read on a 30-day basis.
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.